Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Oxford BioMedica
Oxford BioMedica
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Pharmaceutical
UK vaccine manufacturing nonprofit signs first industry partnership
Oxford Biomedica will be collaborating with VMIC to enable scaled-up manufacture of viral vector-based vaccines
Hi Tech Manufacturing
Oxford Biomedica partners with Microsoft to improve yield of gene therapy via machine learning
Collaboration will see the computing expert develop in silico models and algorithms to address the manufacturing challenges of novel therapies
Recruitment
CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies
Programme will address the projected skills shortage facing public and private employers in the growing cell and gene therapy sector
Design & Build
Oxford BioMedica receives MHRA GMP manufacturing approvals
For lentiviral gene therapy bioprocessing and process development
Design & Build
WHP completes bio-manufacturing facility for Oxford BioMedica
Additional cleanroom space took less than 12 months from concept to completion and creates extra capacity
Manufacturing
Dr Paul Blake becomes Chief Development Officer at Oxford BioMedica
Will take responsibility for the clinical development of pipeline of gene and cell therapies
Research & Development
UK biotechs win Biomedical Catalyst funding of almost £100m
Thirty-three UK companies have received business-led awards
Subscribe now